Publication | Closed Access
Hydroxychloroquine for Primary Progressive Multiple Sclerosis
41
Citations
29
References
2021
Year
HCQ treatment was associated with reduced disability worsening in people with PPMS. HCQ is a promising treatment candidate in PPMS and should be investigated further in randomized controlled clinical trials. ANN NEUROL 2021;90:940-948.
| Year | Citations | |
|---|---|---|
Page 1
Page 1